TOP TEN perturbations for NM_000095 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000095
Selected probe(set): 205713_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000095 (205713_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

breast cancer study 10 (stroma) / noncancerous breast stroma tissue

Relative Expression (log2-ratio):4.8514338
Number of Samples:6 / 6
Experimental breast cancer study 10 (stroma)
Cancerous breast stroma tissue from female patients associated to primary breast infiltrative ductal carcinoma with stromal invasion.
Control noncancerous breast stroma tissue
Noncancerous (normal) tissue cell samples after laser-microdissection from female patients with primary breast infiltrative ductal carcinoma with stromal invasion.

stem cell differentiation study 47 (BMP-2; TGFb; 3d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):4.745475
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; TGFb; 3d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 3 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 3 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

breast cancer study 39 (metastase; brain) / breast cancer study 39 (metastase; bone)

Relative Expression (log2-ratio):-4.649867
Number of Samples:15 / 10
Experimental breast cancer study 39 (metastase; brain)
Metastatic tumor tissue obtained from the brain of female patients with primary breast carcinoma.
Control breast cancer study 39 (metastase; bone)
Metastatic tumor tissue obtained from bone of female patients with primary breast carcinoma.

stem cell differentiation study 47 (BMP-2; TGFb; 7d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):4.6418104
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; TGFb; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

stem cell differentiation study 47 (BMP-2; TGFb; 2d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):4.560874
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; TGFb; 2d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

TGF-?3 study 1 (late) / BMP-2 study 2 (late)

Relative Expression (log2-ratio):4.4121227
Number of Samples:3 / 3
Experimental TGF-?3 study 1 (late)
Cultured mesenchymal stem cells from human bone marrow aspirates of healthy donors. Cells were stimulated with 10ng/ml of recombinant TGF-?3 for 21 days. (Warning: Experiment with gender bias).
Control BMP-2 study 2 (late)
Cultured mesenchymal stem cells from human bone marrow aspirates of healthy donors. Cells were stimulated with 100ng/ml of recombinant BMP-2 for 21 days. (Warning: Experiment with gender bias).

stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 2d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):4.3009233
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 2d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml), transforming growth factor beta (TGFb, 5 ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)

Relative Expression (log2-ratio):-4.299883
Number of Samples:3 / 2
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (ptasc)
CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy.

stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 3d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):4.2967997
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 3d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 3 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml), transforming growth factor beta (TGFb, 5 ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 3 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

smoking study 56 (24 hrs) / smoking study 56 (4 hrs)

Relative Expression (log2-ratio):4.2069025
Number of Samples:3 / 3
Experimental smoking study 56 (24 hrs)
Bronchial epithelium organotypic tissue culture harvested 24 hours (recovery phase) after 4 repetitive exposures to 10% (vol/vol) mainstream cigarette smoke (one 3R4F reference cigarette pro exposure), with 1 hour rest between each treatment. Exposure was performed directly at the air/liquid interface and culture medium was replaced immediately after treatment. The 3D tissue model was generated from primary human respiratory epithelial cells derived from a 67 years old Caucasian non-smoking female donor co-cultured with primary human airway fibroblasts.
Control smoking study 56 (4 hrs)
Bronchial epithelium organotypic tissue culture harvested 4 hours after 4 repetitive exposures to 10% (vol/vol) mainstream cigarette smoke (one 3R4F reference cigarette pro exposure), with 1 hour rest between each treatment. Exposure was performed directly at the air/liquid interface and culture medium was replaced immediately after treatment. The 3D tissue model was generated from primary human respiratory epithelial cells derived from a 67 years old Caucasian non-smoking female donor co-cultured with primary human airway fibroblasts.